SOPHiA GENETICS
SOPH
36 hedge funds and large institutions have $81.4M invested in SOPHiA GENETICS in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
89% more capital invested
Capital invested by funds: $43.2M → $81.4M (+$38.2M)
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
13% more funds holding
Funds holding: 32 → 36 (+4)
0.54% more ownership
Funds ownership: 26.05% → 26.59% (+0.54%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$748K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$463K |
| 3 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$223K |
| 4 |
LCM
Legato Capital Management
San Francisco,
California
|
+$187K |
| 5 |
Morgan Stanley
New York
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$160K |
| 2 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$150K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$150K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$123K |
| 5 |
JP Morgan Chase
New York
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $37.6K | -$10.3K | -2,747 | -26% |
|
27
AssetMark Inc
Concord,
California
| $10.1K | +$1.14K | +306 | +17% |
|
|
NA
28
Nordwand Advisors
Radnor,
Pennsylvania
| $9.42K | – | – | – |
|
|
NA
29
NewEdge Advisors
New Orleans,
Louisiana
| $9.37K | +$5.13K | +1,373 | +223% |
|
|
30
JP Morgan Chase
New York
| $4.15K | -$111K | -29,640 | -97% |
|
31
Wells Fargo
San Francisco,
California
| $3.3K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $3.15K | +$2.25K | +602 | +899% |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$2.24K | +600 | New |
|
34
Osaic Holdings
Scottsdale,
Arizona
| $2.89K | +$1.5K | +402 | +184% |
|
|
PS
35
Principal Securities
Des Moines,
Iowa
| $815 | +$647 | +173 | New |
|
36
Russell Investments Group
London,
United Kingdom
| $245 | – | – | – |
|
|
37
Balyasny Asset Management
Chicago,
Illinois
| – | -$123K | -48,277 | Closed |
|
SOPH Hedge Fund Activity: Q4 2023 in Review
36 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in SOPHiA GENETICS (SOPH) for Q4 2023, worth a combined $81.4M — up 89% from $43.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SOPH positions and 1 closed out — a net gain of 5 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $748K. The largest seller was Millennium Management, cutting an estimated $160K.
- 36 institutional investors held SOPHiA GENETICS (SOPH) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $81.4M of SOPHiA GENETICS stock for Q4 2023, up 89% quarter-over-quarter.
- 6 funds opened new SOPHiA GENETICS positions in Q4 2023 and 1 closed out, a net change of +5 holders.
- The largest SOPHiA GENETICS buyer in Q4 2023 was Parkman Healthcare Partners, an estimated $748K added.
- The largest SOPHiA GENETICS seller in Q4 2023 was Millennium Management, an estimated $160K sold.
Based on aggregated 13F filings for Q4 2023.